TY - JOUR
T1 - An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes
AU - Rosenkilde Laursen, Karin
AU - Bønløkke, Jakob Hjort
AU - Bendstrup, Elisabeth
AU - Bilde, Merete
AU - Glasius, Marianne
AU - Heitmann Gutzke, Vibeke
AU - Puthukkadan Moosakutty, Shamjad
AU - Olin, Anna-Carin
AU - Ravn, Peter
AU - Østergaard, Kirsten
AU - Sigsgaard, Torben
N1 - KAUST Repository Item: Exported on 2021-02-21
Acknowledgements: We are thankful to PExA AB (Göteborg, Sweden) for lending us the PExA® instrument and performing the analysis, and to Nightingale Health Ltd (Helsinki, Finland) for analyzing the blood samples. We would like to thank K.V. Kristensen for skillful assistance in measuring the particle exposure and R.B.Madsen and J.K. Christensen (Dept. of Chemistry, Aarhus University) for their contributions to chemical analyses. We particularly thank the subjects for their participation in the study.
PY - 2020/12/24
Y1 - 2020/12/24
N2 - Background: E-cigarette use has been shown to have short-term acute effects among active users but less is known of the acute passive effects, particularly among individuals with existing respiratory diseases.
Objective: To investigate local and systemic effects of short-term passive vape exposure among patients with mild or moderate chronic obstructive pulmonary disease (COPD).
Methods: In a double-blinded crossover study 16 non-smoking COPD-patients (mean age 68) were randomly exposed for 4 h to passive vape (median PM2.5: 18 µg/m3 (range: 8–333)) and clean air (PM2.5 < 6 µg/m3) separated by 14 days. Particles were measured using an ultrafine particle counter (P-TRAK) and a scanning mobility particle sizer (SMPS). Health effects including Surfactant Protein-A (SP-A) and albumin in exhaled air, spirometry, FeNO, and plasma proteins were evaluated before, right after, and 24 hours after exposure. Participants reported symptoms throughout exposure sessions. Data were analyzed using mixed models.
Results: SP-A in exhaled air was negatively affected by exposure to vape and several plasma proteins increased significantly. Throat irritation was more pronounced during passive vape exposure, while FVC and FEV1 decreased, however, not significantly.
Conclusions: SP-A in exhaled air and some plasma proteins were affected by passive vape in patients with COPD indicating inflammation, showing that passive vape exposure is potentially harmful.
AB - Background: E-cigarette use has been shown to have short-term acute effects among active users but less is known of the acute passive effects, particularly among individuals with existing respiratory diseases.
Objective: To investigate local and systemic effects of short-term passive vape exposure among patients with mild or moderate chronic obstructive pulmonary disease (COPD).
Methods: In a double-blinded crossover study 16 non-smoking COPD-patients (mean age 68) were randomly exposed for 4 h to passive vape (median PM2.5: 18 µg/m3 (range: 8–333)) and clean air (PM2.5 < 6 µg/m3) separated by 14 days. Particles were measured using an ultrafine particle counter (P-TRAK) and a scanning mobility particle sizer (SMPS). Health effects including Surfactant Protein-A (SP-A) and albumin in exhaled air, spirometry, FeNO, and plasma proteins were evaluated before, right after, and 24 hours after exposure. Participants reported symptoms throughout exposure sessions. Data were analyzed using mixed models.
Results: SP-A in exhaled air was negatively affected by exposure to vape and several plasma proteins increased significantly. Throat irritation was more pronounced during passive vape exposure, while FVC and FEV1 decreased, however, not significantly.
Conclusions: SP-A in exhaled air and some plasma proteins were affected by passive vape in patients with COPD indicating inflammation, showing that passive vape exposure is potentially harmful.
UR - http://hdl.handle.net/10754/666793
UR - https://www.tandfonline.com/doi/full/10.1080/20018525.2020.1861580
U2 - 10.1080/20018525.2020.1861580
DO - 10.1080/20018525.2020.1861580
M3 - Article
C2 - 33456728
SN - 2001-8525
VL - 8
SP - 1861580
JO - European Clinical Respiratory Journal
JF - European Clinical Respiratory Journal
IS - 1
ER -